The Phase II study included comparison of the safety, tolerability and pharmacokinetic profiles of PG-free melphalan intravenous formulation to the standard multiple myeloma treatment.
The Captisol-enabled drug is said to provide longer administration durations and slower infusion rates, enabling clinicians to safely achieve a higher dose intensity of pre-transplant chemotherapy.
The trial was conducted in partnership with The University of Kansas Cancer Center was partially funded by the Kansas Bioscience Authority.